# US 2023/0167170 A1 · Compositions comprising anti-vegf and nanoparticles and methods of using the same for the treatment of abnormal or excessive angiogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0167170 A1
- Document ID: US20230167170A1
- Status: Published application
- Kind: A1
- Application number: 17/997,688
- Filed: 2021-05-03
- Published: 2023-06-01
- Earliest claimed: 2020-05-01
- Assignees: Cellviva, LLC
- Applicants: Cellviva, LLC
- Inventors: Randal Tanh Hoang PHAM; Eric F. BERNSTEIN; Dale KOOP
- Web page: https://patentgrep.com/patent/US20230167170A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6845: {the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition for treating abnormal or excessive angiogenesis, such as pyogenic granuloma comprising an anti-vascular endothelial growth factor (anti-VEGF) agent (e.g., an antibody or small molecule inhibitor of VEGF signaling) and a carrier comprising nanoparticles. Methods of treating abnormal or excessive angiogenesis by administering a composition comprising an anti-VEGF agent and nanoparticles, alone or in combination with administering an anti-inflammatory steroid, and administering a non-steroidal anti-inflammatory drug (NSAID) to a subject. Devices for administering the composition for treating pyogenic granuloma are also disclosed.

## Claims

### Claim 1

A composition for the treatment abnormal or excessive angiogenesis, comprising:
at least one anti-vascular endothelial grown factor (anti-VEGF) antibody comprising bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, or combination thereof; and
a carrier comprising nanoparticles, wherein the nanoparticles are organic, inorganic, or a combination thereof.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The composition of claim 1, wherein the anti-VEGF antibody comprises bevacizumab having a concentration of bevacizumab in a solution for administration of 1.25 mg/0.05 mL.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the nanoparticles are organic, wherein the organic nanoparticles comprise porphysome nanovesicles, or conductive polymer nanoparticles.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The composition of claim 5, wherein the organic nanoparticles comprise at least one of paclitaxel-loaded polymeric micelles, liposomal doxorubicin, or paclitaxel-loaded human serum albumin nanoaggregate.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the nanoparticles are inorganic, wherein the inorganic nanoparticles comprise semiconductor quantum dots, super paramagnetic iron oxide, and gold-based compounds.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The composition of claim 1, wherein the nanoparticles are a combination of porphyrin-based organic nanoparticles and the porphyrin/cholic acid hybrid polymers.

### Claim 11 (depends on 1)

The composition of claim 1, further comprising an anti-inflammatory steroid, a non-steroidal anti-inflammatory drug (NSAID), or both, wherein the anti-inflammatory steroid is alclometason, diflorasone, fluocinonide, triamcinolone, prednicarbate, or prednisolone and the NSAID is diclofenac, ketorolac, neparenac, or bromfenac.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The composition of claim 1, wherein the pyogenic granuloma is present on the periorbital and/or orbital areas of the eye, or on the skin.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The composition of claim 1, wherein the area containing abnormal or excessive angiogenesis comprises pyogenic granuloma, infantile hemangioma, hemangioma of infancy, congenital hemangioma, tufted hemangioma, spindle cell hemangioma, epithelioid hemangioma, kaposiform hemangioendothelioma, retiform hemangioendothelioma, papillary intralymphatic angioendothelioma, dabska tumor, composite hemangioendothelioma, Kaposi sarcoma, angiosarcoma, Epithelioid hemangioendothelioma, capillary malformation, lymphatic malformation, venous malformation, arteriovenous malformation, arteriovenous fistula, capillary-lymphatic malformation, capillary-arteriovenous malformation, capillary-lymphatic-arteriovenous malformation, capillary-venous-arteriovenous malformation, capillary-lymphatic-venous-arteriovenous malformation.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the area containing abnormal or excessive angiogenesis comprises at least one eye, eyelid and orbital lesions selected from: Cavernous hemangiomas, Cavernous malformations, Arteriovenous malformations, Arteriovenous fistulas, Aneurysms, Lymphangiomas, Hemangiopericytomas, Malignant hemangioendotheliomas (angiosarcomas), Angiolymphoid hyperplasias with eosinophilia (Kimura's disease), Racemose hemangiomas of Wyburn-Mason syndrome, Hemangioblastomas, Orbital varices, Venous lymphatic malformations, Choroidal hemangiomas, Choroidal melanomas, and Coats Disease.

### Claim 18

A method of treating abnormal or excessive angiogenesis, the method comprising:
administering to an area containing abnormal or excessive angiogenesis a composition containing at least one anti-VEGF antibody and nanoparticles, wherein the nanoparticles are organic, inorganic, or a combination thereof,
administering an anti-inflammatory steroid; and
administering a non-steroidal, anti-inflammatory drug (NSAID).

### Claim 19 (depends on 18)

The method of claim 18, wherein the steps can be performed in any order or simultaneously.

### Claim 20 (depends on 18)

The method of claim 18, wherein the anti-VEGF antibody comprises bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, or combination thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein the anti-VEGF antibody is bevacizumab and is administered at a dosage of 1.25 mg.

### Claim 22 (depends on 18)

The method of claim 18, wherein the nanoparticles are organic and comprise porphysome nanovesicles, or conductive polymer nanoparticles.

### Claim 23 (depends on 18)

The method of claim 18, wherein the organic nanoparticles comprise at least one of paclitaxel-loaded polymeric micelles, liposomal doxorubicin, or paclitaxel-loaded human serum albumin nanoaggregate.

### Claim 24 (depends on 18)

The method of claim 18, wherein the nanoparticles are inorganic and comprise semiconductor quantum dots, super paramagnetic iron oxide, and gold-based compounds.

### Claim 25

(canceled)

### Claim 26 (depends on 18)

The method of claim 18, wherein the nanoparticles are a combination of porphyrin-based organic nanoparticles and the porphyrin/cholic acid hybrid polymers.

### Claim 27 (depends on 18)

The method of claim 18, wherein the composition is administered by injection or topically.

### Claim 28 (depends on 18)

The method of claim 18, wherein the composition, the anti-inflammatory steroid, and the NSAID are all administered on the same day or individually on separate days.

### Claim 29 (depends on 28)

The method of claim 28, wherein the composition, the anti-inflammatory steroid, and the NSAID are all administered at least once.

### Claim 30 (depends on 18)

The method of claim 18, wherein the anti-inflammatory steroid is one or more of alclometason, diflorasone, fluocinonide, triamcinolone, prednicarbate, or prednisolone.

### Claim 31 (depends on 30)

The method of claim 30, wherein the anti-inflammatory steroid is triamcinolone and is administered at a dose of 12 mg.

### Claim 32

(canceled)

### Claim 33 (depends on 18)

The method of claim 18, wherein the NSAID is one or more of diclofenac, ketorolac, neparenac, or bromfenac.

### Claim 34 (depends on 18)

The method of claim 18, wherein the area containing abnormal or excessive angiogenesis is present in the eye or on the skin.

### Claim 35

(canceled)

### Claim 36 (depends on 18)

The method of claim 18, wherein the area containing abnormal or excessive angiogenesis comprises pyogenic granuloma, infantile hemangioma, hemangioma of infancy, congenital hemangioma, tufted hemangioma, spindle cell hemangioma, epithelioid hemangioma, kaposiform hemangioendothelioma, retiform hemangioendothelioma, papillary intralymphatic angioendothelioma, dabska tumor, composite hemangioendothelioma, Kaposi sarcoma, angiosarcoma, Epithelioid hemangioendothelioma, capillary malformation, lymphatic malformation, venous malformation, arteriovenous malformation, arteriovenous fistula, capillary-lymphatic malformation, capillary-arteriovenous malformation, capillary-lymphatic-arteriovenous malformation, capillary-venous-arteriovenous malformation, capillary-lymphatic-venous-arteriovenous malformation.

### Claim 37 (depends on 18)

The method of claim 18, wherein the area containing abnormal or excessive angiogenesis comprises at least one eye, eyelid and orbital lesions selected from: Cavernous hemangiomas, Cavernous malformations, Arteriovenous malformations, Arteriovenous fistulas Aneurysms, Lymphangiomas, Hemangiopericytomas, Malignant hemangioendotheliomas (angiosarcomas), Angiolymphoid hyperplasias with eosinophilia (Kimura's disease), Racemose hemangiomas of Wyburn-Mason syndrome, Hemangioblastomas, Orbital varices, Venous lymphatic malformations, Choroidal hemangiomas, Choroidal melanomas, and Coats Disease.

### Claim 38 (depends on 1)

A device for administering the composition of claim 1, the device configured to administer the composition by at least one method selected from intravenous, subconjunctival, subtenon, episcleral, intrascleral, subscleral, intraperitoneal, epidural, intrathecal, intramuscular, intraluminal, intratracheal, epidermal, intradermal, subdermal or subcutaneous.

### Claim 39 (depends on 38)

The device of claim 38, wherein said device comprises one part of a kit, wherein the kit comprises at least one cartridge, syringe, vial or applicator preloaded with a predetermined amount of the pharmaceutical composition.

### Claim 40

(canceled)
